Skip to main
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Annexon is well-positioned for success with a promising pipeline of potential treatments for a variety of classical complement-mediated diseases, including autoimmune and neurodegenerative disorders, as well as ocular diseases. Their lead program for GBS has already shown positive results and their drug vonaprument has a high potential for success in Phase 3 trials. Investors can also be reassured by the company's strong leadership, including the Executive Vice President who is leading innovation and scientific strategy, and the potential for significant peak sales of $500 million.

Bears say

Annexon is currently in the clinical stage and has no approved products on the market, leaving the potential for future revenue uncertain. Additionally, the company's financials show a decrease in total assets and an increase in liabilities, indicating potential financial struggles. With competition in the C1q inhibition market and the uncertainty of future success, Annexon's stock may see a decline in the coming years.

Annexon, Inc (ANNX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Buy based on their latest research and market trends.

According to 6 analysts, Annexon, Inc (ANNX) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.